Enanta Total Assets from 2010 to 2024

ENTA Stock

USD 8.56 0.45 4.99%

Enanta Pharmaceuticals' Total Assets are increasing over the years with slightly volatile fluctuation. Total Assets are expected to dwindle to about 327.6 M. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2010-09-30

Previous Quarter

413.6 M

Current Value

398.8 M

Quarterly Volatility

149.7 M

Credit Downgrade

Yuan Drop

Covid

Check Enanta Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Enanta Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.9 M, Interest Expense of 3.1 M or Selling General Administrative of 63.9 M, as well as many indicators such as Price To Sales Ratio of 2.53, Dividend Yield of 0.0 or PTB Ratio of 1.92. Enanta financial statements analysis is a perfect complement when working with Enanta Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Enanta Pharmaceuticals Correlation against competitors.

For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.

Latest Enanta Pharmaceuticals' Total Assets Growth Pattern

Below is the plot of the Total Assets of Enanta Pharmaceuticals over the last few years. Total assets refers to the total amount of Enanta Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Enanta Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Enanta Pharmaceuticals' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Enanta Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 462.27 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Enanta Total Assets Regression Statistics

	Arithmetic Mean	315,361,297
	Geometric Mean	246,008,919
	Coefficient Of Variation	52.29
	Mean Deviation	135,230,904
	Median	327,566,208
	Standard Deviation	164,903,145
	Sample Variance	27193T
	Range	505.5M
	R-Value	0.85
	Mean Square Error	8276.4T
	R-Squared	0.72
	Significance	0.000068
	Slope	31,231,225
	Total Sum of Squares	380702.7T

Enanta Total Assets History

	2024	327.6 M
	2023	531.6 M
	2022	462.3 M
	2021	375.4 M
	2020	438.8 M
	2019	486.1 M
	2018	489.8 M

Other Fundumenentals of Enanta Pharmaceuticals

Intangibles To Total Assets

Enanta Pharmaceuticals Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Short Term Investments	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue	Long Term Debt	Net Tangible Assets	Capital Surpluse	Long Term Investments	Short Long Term Debt	Short Term Debt	Long Term Debt Total	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.85	-0.8	0.26	0.8	0.81	0.97	0.28	0.98	0.78	0.62	0.9	0.88	0.93	0.79	-0.12	0.95	0.83	0.9	0.24	0.82	0.53
Total Stockholder Equity	0.85		-0.72	0.62	0.81	0.71	0.78	-0.16	0.79	0.72	0.3	0.74	0.71	0.89	0.44	0.16	0.8	0.75	0.69	0.58	0.6	0.14
Net Debt	-0.8	-0.72		-0.29	-0.6	-0.55	-0.74	-0.26	-0.79	-0.56	-0.38	-0.74	-0.76	-0.81	-0.49	0.1	-0.76	-0.68	-0.73	-0.3	-0.75	-0.33
Retained Earnings	0.26	0.62	-0.29		0.39	0.26	0.2	-0.75	0.19	0.15	-0.51	0.07	0.04	0.43	-0.28	0.58	0.29	0.35	0.13	0.86	0.04	-0.61
Accounts Payable	0.8	0.81	-0.6	0.39		0.82	0.67	0.04	0.73	0.53	0.41	0.81	0.79	0.84	0.64	0.28	0.77	0.85	0.8	0.5	0.58	0.29
Net Receivables	0.81	0.71	-0.55	0.26	0.82		0.73	0.19	0.79	0.55	0.52	0.83	0.84	0.8	0.69	-0.03	0.8	0.89	0.89	0.31	0.69	0.38
Short Term Investments	0.97	0.78	-0.74	0.2	0.67	0.73		0.33	0.99	0.74	0.63	0.88	0.84	0.88	0.78	-0.3	0.89	0.79	0.86	0.17	0.87	0.55
Total Liab	0.28	-0.16	-0.26	-0.75	0.04	0.19	0.33		0.35	0.16	0.79	0.48	0.5	0.2	0.61	-0.64	0.24	0.17	0.37	-0.57	0.51	0.83
Total Current Assets	0.98	0.79	-0.79	0.19	0.73	0.79	0.99	0.35		0.74	0.64	0.91	0.89	0.9	0.82	-0.27	0.92	0.84	0.91	0.18	0.88	0.57
Common Stock	0.78	0.72	-0.56	0.15	0.53	0.55	0.74	0.16	0.74		0.52	0.63	0.59	0.61	0.58	-0.11	0.69	0.48	0.57	0.03	0.5	0.42
Property Plant Equipment	0.62	0.3	-0.38	-0.51	0.41	0.52	0.63	0.79	0.64	0.52		0.77	0.77	0.49	0.85	-0.57	0.59	0.43	0.64	-0.39	0.63	0.87
Current Deferred Revenue	0.9	0.74	-0.74	0.07	0.81	0.83	0.88	0.48	0.91	0.63	0.77		0.98	0.91	0.82	-0.29	0.86	0.85	0.91	0.2	0.86	0.63
Long Term Debt	0.88	0.71	-0.76	0.04	0.79	0.84	0.84	0.5	0.89	0.59	0.77	0.98		0.89	0.83	-0.27	0.85	0.88	0.95	0.21	0.88	0.64
Net Tangible Assets	0.93	0.89	-0.81	0.43	0.84	0.8	0.88	0.2	0.9	0.61	0.49	0.91	0.89		0.64	-0.02	0.89	0.89	0.86	0.5	0.83	0.38
Capital Surpluse	0.79	0.44	-0.49	-0.28	0.64	0.69	0.78	0.61	0.82	0.58	0.85	0.82	0.83	0.64		-0.35	0.77	0.68	0.86	-0.19	0.73	0.82
Long Term Investments	-0.12	0.16	0.1	0.58	0.28	-0.03	-0.3	-0.64	-0.27	-0.11	-0.57	-0.29	-0.27	-0.02	-0.35		-0.04	-0.05	-0.19	0.5	-0.45	-0.55
Short Long Term Debt	0.95	0.8	-0.76	0.29	0.77	0.8	0.89	0.24	0.92	0.69	0.59	0.86	0.85	0.89	0.77	-0.04		0.77	0.88	0.2	0.71	0.46
Short Term Debt	0.83	0.75	-0.68	0.35	0.85	0.89	0.79	0.17	0.84	0.48	0.43	0.85	0.88	0.89	0.68	-0.05	0.77		0.93	0.53	0.85	0.36
Long Term Debt Total	0.9	0.69	-0.73	0.13	0.8	0.89	0.86	0.37	0.91	0.57	0.64	0.91	0.95	0.86	0.86	-0.19	0.88	0.93		0.24	0.87	0.57
Net Invested Capital	0.24	0.58	-0.3	0.86	0.5	0.31	0.17	-0.57	0.18	0.03	-0.39	0.2	0.21	0.5	-0.19	0.5	0.2	0.53	0.24		0.22	-0.48
Net Working Capital	0.82	0.6	-0.75	0.04	0.58	0.69	0.87	0.51	0.88	0.5	0.63	0.86	0.88	0.83	0.73	-0.45	0.71	0.85	0.87	0.22		0.63
Capital Stock	0.53	0.14	-0.33	-0.61	0.29	0.38	0.55	0.83	0.57	0.42	0.87	0.63	0.64	0.38	0.82	-0.55	0.46	0.36	0.57	-0.48	0.63

Click cells to compare fundamentals

About Enanta Pharmaceuticals Financial Statements

Enanta Pharmaceuticals stakeholders use historical fundamental indicators, such as Enanta Pharmaceuticals' Total Assets, to determine how well the company is positioned to perform in the future. Although Enanta Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Enanta Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Enanta Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Enanta Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Total Assets	531.6 M	327.6 M
Intangibles To Total Assets	(0.02)	(0.02)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Enanta Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enanta Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enanta Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enanta Pharmaceuticals Stock:

How To Invest In Enanta

Details

Is Enanta Stock a good investment?

Details

What is Enanta Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Enanta Pharmaceuticals Correlation against competitors.

For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.

You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enanta Pharmaceuticals. If investors know Enanta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enanta Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.66)

Earnings Share

(5.45)

Revenue Per Share

3.407

Quarterly Revenue Growth

(0.05)

Return On Assets

(0.17)

The market value of Enanta Pharmaceuticals is measured differently than its book value, which is the value of Enanta that is recorded on the company's balance sheet. Investors also form their own opinion of Enanta Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Enanta Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enanta Pharmaceuticals' market value can be influenced by many factors that don't directly affect Enanta Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Enanta Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enanta Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enanta Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Enanta Total Assets from 2010 to 2024

Latest Enanta Pharmaceuticals' Total Assets Growth Pattern

Enanta Total Assets Regression Statistics

Enanta Total Assets History

Other Fundumenentals of Enanta Pharmaceuticals

Enanta Pharmaceuticals Total Assets component correlations

About Enanta Pharmaceuticals Financial Statements

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY